The Role of b-Arrestins in Cancer - Progress in Molecular Biology and Translational Science - page 400

68. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with
imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a chil-
dren's oncology group study. J Clin Oncol . 2009;27(31):5175 - 5181.
69. Liu H, Long J, Zhang PH, et al. Elevated beta-arrestin1 expression correlated with risk
stratification in acute lymphoblastic leukemia. Int J Hematol . 2011;93(4):494 - 501.
70. Fereshteh M, Ito T, Kovacs JJ, et al. beta-Arrestin2 mediates the initiation and progres-
sion of myeloid leukemia. Proc Natl Acad Sci USA . 2012;109(31):12532 - 12537.
71. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer.
Nat Rev Cancer . 2001;1(1):34 - 45.
72. Lakshmikanthan V, Zou L, Kim JI, et al. Identification of betaArrestin2 as a corepressor
of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA . 2009;106
(23):9379 - 9384.
73. Hennenberg M, Schlenker B, Roosen A, et al. beta-Arrestin-2 is expressed in human
prostate smooth muscle and a binding partner of alpha1A-adrenoceptors. World
J Urol . 2011;29(2):157 - 163.
74. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III trans-
forming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Cancer Res . 2007;67(3):1090 - 1098.
75. Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer
cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci
USA . 2009;106(20):8221- 8226.
76. Zhang P, He X, Tan J, Zhou X, Zou L. beta-Arrestin2 mediates beta-2 adrenergic
receptor signaling inducing prostate cancer cell progression. Oncol Rep . 2011;26
(6):1471 - 1477.
77. Heinrich EL, Lee W, Lu J, Lowy AM, Kim J. Chemokine CXCL12 activates dual
CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.

J Transl Med . 2012;10:68.
78. Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, Kim J. Chemokine receptor
CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK
dependent pathways. Pancreas . 2010;39(1):81 - 87.
79. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of
pancreatic cancer tumorigenesis. Nature . 2003;425(6960):851 - 856.
80. ChenW, Ren XR, Nelson CD, et al. Activity-dependent internalization of smoothened
mediated by beta-arrestin 2 and GRK2. Science . 2004;306(5705):2257 - 2260.
81. Mandell JW, Glass G, Gianchandani EP, et al. Dephosphorylation of beta-arrestin 1 in
glioblastomas. J Neuropathol Exp Neurol . 2009;68(5):535- 541.
82. Michal AM, Peck AR, Tran TH, et al. Differential expression of arrestins is a predictor of
breast cancer progression and survival. Breast Cancer Res Treat . 2011;130(3):791 - 807.
83. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits
intracranial growth of primary brain tumors. Proc Natl Acad Sci USA . 2003;100
(23):13513 - 13518.
84. Gravel S, Malouf C, Boulais PE, et al. The peptidomimetic CXCR4 antagonist
TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem .
2010;285(49):37939- 37943.
85. Odemis V, Lipfert J, Kraft R, et al. The presumed atypical chemokine receptor CXCR7
signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Glia . 2012;60(3):372 - 381.
86. Lundgren K, Tobin NP, Lehn S, et al. Stromal expression of beta-arrestin-1 predicts
clinical outcome and tamoxifen response in breast cancer. J Mol Diagn . May 2011;13
(3):340 - 351.